Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)47.13
  • Today's Change-0.270 / -0.57%
  • Shares traded596.13k
  • 1 Year change-21.11%
  • Beta1.3320
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Haohai Biological Technology Co Ltd is a China-based company mainly engaged in the production and sale of biological products, medical hyaluronic acid and intraocular lenses, research and development of bioengineering and pharmaceuticals, and provision of related services. The ophthalmology business has covered cataract treatment, myopia prevention and control, refractive correction, ocular surface medication, and optometry materials such as intraocular lenses and orthokeratology lenses. Medical beauty and wound care products include hyaluronic acid dermal fillers, hyaluronic acid gel for skin and mucosal superficial tissue supplementation. Orthopedic products include orthopedic joint cavity viscoelastic supplements and others. Anti-adhesion and hemostasis products include medical chitosan (for anti-adhesion), medical sodium hyaluronate gel and collagen sponge. The Company mainly conducts its businesses in domestic and foreign markets.

  • Revenue in CNY (TTM)2.52bn
  • Net income in CNY384.21m
  • Incorporated2007
  • Employees2.16k
  • Location
    Shanghai Haohai Biological Technology Co Ltd4F, No 2 Building, Alley 139Anshun Road, Changning DistrictSHANGHAI 200336ChinaCHN
  • Phone+86 2 152293555
  • Fax+86 2 152293558
  • Websitehttps://www.3healthcare.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
HOB Biotech Group Corp Ltd387.48m36.43m9.03bn529.00243.7410.76--23.310.58380.58386.1713.230.39381.507.30732,482.303.707.244.418.6457.8764.539.4016.211.0714.220.080542.822.019.20-22.24-10.4334.88--
Shinva Medical Instrument Co Ltd9.58bn508.92m9.40bn8.14k18.521.20--0.9820.8370.83715.7812.910.62862.204.501,177,051.003.304.126.278.9724.4625.095.245.610.8863--0.12421.150.08742.715.75-4.2914.3026.58
Sino Medical Sciences Technology Inc504.11m29.36m9.54bn691.00323.3210.54--18.920.07060.07061.212.170.3851.6342.71729,533.101.69-5.652.05-6.4563.9263.654.40-21.721.712.660.2102--33.641.03103.78-55.92-17.21--
Shanghai Runda Medical Technology Co Ltd7.40bn-157.84m9.66bn3.14k--2.31--1.31-0.2609-0.260912.466.920.52373.681.462,360,202.00-0.55773.81-1.4910.1921.9826.78-1.065.440.97231.160.560515.85-9.133.34-79.77-29.14-4.52--
Shanghai Haohai Biological Tech Co Ltd2.52bn384.21m10.06bn2.16k28.711.94--3.991.651.6510.8324.490.35121.537.841,169,728.004.944.585.965.2669.1370.3914.0714.673.24--0.065642.371.6410.951.042.55-1.8614.87
Qingdao Haier Biomedical Co Ltd2.26bn255.88m10.33bn2.81k40.072.39--4.560.81440.81447.2113.640.40084.315.12806,199.104.6810.875.9214.1245.3149.2111.6724.082.41--0.020528.140.128817.67-9.7115.03-5.5321.16
Xiangyu Medical Co Ltd773.93m73.51m11.01bn2.34k143.715.43--14.230.47890.47895.0712.670.25481.0111.40330,597.702.358.543.2610.1765.9866.789.2228.370.9871--0.238732.49-0.171711.71-54.68-4.4183.55--
Shanghai Microport EP MedTech Co Ltd458.70m52.26m11.11bn500.00212.526.20--24.210.1110.1110.97473.810.23951.336.85917,403.002.730.90842.910.957958.2464.9511.394.0910.17--0.00320.0025.5128.61815.36--35.67--
Beijing Wandong Medical Technolgy Co Ltd1.62bn14.41m11.31bn1.19k965.192.41--6.980.01670.01672.266.660.29372.732.991,360,016.000.26234.510.3045.2131.5942.820.893314.914.80--0.003943.2523.269.18-16.54-1.40-1.3921.06
Data as of Feb 10 2026. Currency figures normalised to Shanghai Haohai Biological Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.60%Per cent of shares held by top holders
HolderShares% Held
Hwabao WP Fund Management Co., Ltd.as of 31 Mar 20252.45m1.26%
China Southern Asset Management Co., Ltd.as of 30 Jun 2025789.46k0.41%
China Asset Management Co., Ltd.as of 30 Jun 2025783.65k0.40%
Bosera Asset Management Co., Ltd.as of 30 Jun 2025586.46k0.30%
The Vanguard Group, Inc.as of 07 Jan 2026554.80k0.29%
Penghua Fund Management Co., Ltd.as of 30 Jun 2025549.68k0.28%
GF Fund Management Co., Ltd.as of 30 Jun 2025525.96k0.27%
Yinhua Fund Management Co., Ltd.as of 30 Jun 2025274.48k0.14%
E Fund Management Co., Ltd.as of 30 Jun 2025266.42k0.14%
Maxwealth Fund Management Co., Ltd.as of 30 Jun 2025209.98k0.11%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.